Dissolution Test for Solid Oral Dosage Forms: WHO publishes Draft for Comments
![Statistical Simulations for Enhanced Understanding of Analytical Performance - Live Webinar](files/eca/userImages/training.img/Z-ECA-Webinar-Statistical-Simulations.jpg)
Recommendation
Monday, 9 September 2024 14.00 - 16.00 h
In the pharmaceutical industry, drug dissolution testing is routinely used as a key test parameter for assessing the performance of solid and semi-solid dosage forms in both drug development and quality control. A dissolution test measures the amount of drug that goes into solution over a period of time under standardized conditions. It is used to assure batch-to-batch quality, to provide process control, and to substitute in vivo studies under certain circumstances.
The World Health Organization (WHO) has now published a draft proposal for revision in The International Pharmacopoeia (Ph. Int.). The Working document QAS/20.837 from June 2020 relates to chapter 5.5 entitled DISSOLUTION TEST FOR SOLID ORAL DOSAGE FORMS. A section for the analysis of suspensions and powders for oral suspension was added. Comments are sought on the new section.
The document will be posted on the WHO Medicines website under “Current Projects”. The deadline for comments is 31 August 2020.
Related GMP News
24.07.2024FDA Warning Letter to Chinese OTC Manufacturer for Lack of Analytical Test Data
10.07.2024Pharmeuropa: Two Revised Chapters on Dissolution Testing published for comments
03.07.2024FDA Warning Letter: GMP Requirements also apply to HPLC Analyses for Internal Use
12.06.2024NMPA Announcement on Application of ICH Q2(R2) and Q14 Principles
22.05.2024Q&As from the Live Online Training "Introduction to the AQCG's new AIQSV Guide" - Part 1
22.05.2024FDA Warning Letter to Contract Testing Laboratory in Uruguay due to Data Integrity Violations